Premium
The Role for Interleukin‐12 Therapy of Cutaneous T Cell Lymphoma
Author(s) -
ROOK ALAIN H.,
ZAKI MOHAMED H.,
WYSOCKA MARIA,
WOOD GARY S.,
DUVIC MADELEINE,
SHOWE LOUISE C.,
FOSS FRANCINE,
SHAPIRO MICHAEL,
KUZEL TIMOTHY M.,
OLSEN ELISE A.,
VONDERHEID ERIC C.,
LALIBERTE ROBERT,
SHERMAN MATTHEW L.
Publication year - 2001
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2001.tb03721.x
Subject(s) - cutaneous t cell lymphoma , lymphoma , medicine , cd8 , immune system , t cell , concomitant , lesion , cytotoxic t cell , biopsy , interleukin 2 , interleukin , immunology , oncology , cytokine , pathology , biology , mycosis fungoides , in vitro , biochemistry
A bstract : Recent phase I and phase II trials using recombinant human interleukin‐12 (rhIL‐12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8 + and/or TIA‐1 + T cells. These results suggest that rhIL‐12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL‐12.